Table IV.

 Treatment‐Emergent AEs Occurring in ≥2% of Patients in Any Group and Prespecified AEs

N	Age		Obesity BMI		Diabetes Mellitus Type 2		Baseline SBP
	≥65 y	<65 y	≥30 kg/m 2	<30 kg/m 2	With	Without a	≥180 mm Hg	<180 mm Hg
	53	415	236	229	52	416	135	332
Total subjects with AEs, %	26.4	30.4	28.2	31.7	25.0	30.5	31.1	29.5
Headacheb	3.8	4.1	3.3	5.0	1.9	4.3	6.7	3.0
Dizzinessb	1.9	3.6	3.3	3.6	1.9	3.6	3.7	3.3
Dizziness posturalb	0	0.2	0.4	0	0	0.2	0	0.3
Bronchitis	0	1.4	0.8	1.8	3.8	1.0	0	1.8
Upper respiratory tract infection	0	1.4	0.8	1.8	3.8	1.0	1.5	1.2
Blood glucose increased	1.9	0.2	0.4	0.5	3.8	0	1.5	0
Somnolence	0	0.7	0.8	0.5	0	0.7	2.2	0
Nasopharyngitis	1.9	1.7	2.0	1.4	0	1.9	1.5	1.8
Migraineb	0	0.2	0	0.5	0	0.2	0.7	0
Hyperkalemiab	0	0.2	0.4	0	0	0.2	0	0.3
Hypokalemiab	0	0.2	0	0.5	1.9	0	0	0.3
Blood potassium decreasedb	0	0.5	0.8	0	0	0.5	0.7	0.3
Hypotensionb	0	0.5	0.8	0	0	0.5	0.7	0.3
Orthostatic hypotensionb	0	0.2	0.4	0	0	0.2	0	0.3
Syncopeb	0	0	0	0	0	0	0	0

Abbreviations: AEs, adverse events; BMI, body mass index; SBP, systolic blood pressure. ^aOr unknown. ^bPrespecified AEs.